



INTERNATIONAL KIDNEY CANCER  
SYMPOSIUM: NORTH AMERICA

# Symposium Guide

FRIDAY & SATURDAY, NOVEMBER 4–5, 2022

TABLE OF CONTENTS

Welcome Letters 3

About the Kidney Cancer Association 5

Continuing Medical Education Information 8

Program Agenda 11

Poster Listings 23

Sponsors and Exhibitors 29

Hyatt Regency Map 30

JOIN THE CONVERSATION ON SOCIAL MEDIA

We encourage all attendees to share their IKCS: North America experience on social media!

#IKCSNA22  
@KidneyCancer



WIFI INFO

NETWORK

@Hyatt\_events

PASSWORD

IKCSNA22

SCAN TO ACCESS  
APP/HYBRID MEETING  
PLATFORM



## The International Kidney Cancer Symposium

The Kidney Cancer Association (KCA) presents the International Kidney Cancer Symposium: North America, an opportunity for physicians, researchers, academics, and industry professionals from across the region to join and exchange ideas that will direct the future of kidney cancer research and treatment in the ultimate pursuit of a cure.

IKCS meetings are a front-row seat to emerging research, noteworthy breakthroughs, current challenges, and promising treatments in kidney cancer. The community feel promotes learning, networking, and unparalleled opportunities for mentorship and collaboration.



### HEALTH AND SAFETY INFORMATION

IKCS: North America will follow all local health and safety policies.

Additional information is available on our website at

**[kcameetings.org/2022-ikcs-north-america](https://kcameetings.org/2022-ikcs-north-america)**

## WELCOME FROM KCA'S PRESIDENT & CEO

### **We are pleased to welcome you to the 2022 IKCS: North America!**

We are grateful to be together in-person once again in Austin, Texas, for an exciting program that showcases the best in kidney cancer research and discovery. We also welcome those joining virtually from around the world to exchange ideas that will direct the future of kidney cancer research.

This year, we are honored to have David McDermott, MD, Chief of Medical Oncology from Beth Israel Deaconess Medical Center deliver the Keynote Lecture. In addition, this year's meeting presents two newly established awards: The Christopher G. Wood Rising Star Award, established in memory of Christopher G. Wood, former Chairman of the Board of Directors, to commemorate his commitment to the kidney cancer community. This award is given to the early-career scientist or physician within seven years of an initial faculty appointment who embodies Chris' spirit for community and collaboration. Also new this year is The Nicholas J. Vogelzang Humanitarian Award, dedicated and awarded to our late KCA Co-Founder, kidney cancer trailblazer, and colleague Nicholas J. Vogelzang, MD, FACP, FASCO. Thank you to all of this year's award recipients for your outstanding contributions to the kidney cancer field.

Make sure to spend time in the exhibit hall, network with fellow attendees both in-person and virtually (use the official Twitter hashtag #IKCSNA22), and don't forget to collect your CME credits.

We thank those who worked diligently to bring us a dynamic event while prioritizing health and safety. Among those are:

- Our presenters and panelists
- Our sponsors, exhibitors, and attendees
- Our Planning Committee: Eric A. Singer, MD, MA, FACS (Co-Chair); Tian Zhang, MD (Co-Chair); Maria Carlo, MD; Jodi Marachie, MD; Vitaly Margulis, MD; Bradley McGregor, MD; Phillip Pierorazio, MD; Kiran Virdee, RN, BSN, CCRN; Laura Wood, RN, MSN, OCN; Yousef Zakharia, MD

Your contributions to this journey and service to patients and families are an inspiration. We at the KCA are proud to support you and help forge new paths to unlocking the cure!

Sincerely,



**Gretchen E. Vaughan**

*President and CEO, Kidney Cancer Association*

*#UnstoppableTogether*



## WELCOME FROM THE CITY OF AUSTIN



Dear 2022 IKCS: North America attendees,

Welcome to Austin! We are thrilled that the Kidney Cancer Association chose Austin to host the International Kidney Cancer Symposium. On behalf of Visit Austin and the hospitality community, it is my pleasure to invite you to enjoy our city.

As you may know, Austin is a city built on cultivating big ideas. Willie Nelson came here to reinvent country music. Michael Dell reinvented the assembly line in his dorm room at the University of Texas. And John Mackey with Whole Foods reinvented what grocery stores can be—all right here in Austin, a special city where great ideas come to life. Great ideas are created when people from all walks of life come together, and that's what I hope will happen at your conference this year.

While you are here, I encourage you to experience all that Austin has to offer. Visit our parks, open air venues, restaurants, Lady Bird Lake hike and bike trail, and the many entertainment districts, including Sixth Street, Rainey Street, Downtown (the home of Austin City Limits), and the Market District. We hope you all have a great time and learn why Austin is a favorite national and international destination.

Thank you again for choosing Austin for your annual conference. We hope you enjoy your stay!

Sincerely,

A handwritten signature in black ink that reads "Tom Noonan". The signature is fluid and cursive, with a long horizontal line extending from the end.

**Tom Noonan**

*President & CEO*

*Visit Austin*

## ABOUT THE KCA

The Kidney Cancer Association was founded in 1990 by Eugene P. Schonfeld and a small group of patients and doctors in Chicago, Illinois, and has grown into an international non-profit organization. The KCA promotes scientific advances through two annual research symposiums and a robust grant program, participates in legislative advocacy, and seeks to be a source of education and resources for patients, caregivers, and anyone impacted by kidney cancer.

**OUR VISION** is to be the universal leader in finding the cure for kidney cancer.

**OUR MISSION** is to be a global community dedicated to serving and empowering patients and caregivers, and leading change through advocacy, research, and education.

## MAIL DONATIONS TO

Please send donations to our secure lock-box:

**Kidney Cancer Association**

**PO Box 676226, Dallas, TX 75267-6226**

USA: (800) 850-9132

**INTERNATIONAL:** +1 847 332 1051

**EMAIL:** [office@kidneycancer.org](mailto:office@kidneycancer.org)

*"One of the Association's most important contributions is its support of the physicians, nurses, and cancer care team members who care for patients with kidney cancer. Through our educational activities, we help ensure that the latest medical advances and best practices are shared. Our global medical conferences bring together the world's leading technology and treatment options."*

**Gretchen E. Vaughan**

*President and CEO, Kidney Cancer Association*



**Stay up to date with the data**  
**INLYTA® (axitinib) + pembrolizumab**



Scan to visit the  
**Virtual Booth**



Scan to see the full  
**Prescribing Information**

*To learn more,*

**visit Booth #110**



Visit the **Merck** and **Eisai** booths  
for more information.

Learn more at **KeytrudaLenvimaHCP.com**



Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates.  
All rights reserved. US-KLR-00378 09/22  
The trademarks used are owned by their respective owners.

KCA STAFF

Gretchen E. Vaughan President & CEO Houston, Texas	Radha Chitale Senior Director of Communications Washington, D.C.	Stephanie Shirley Director of Advancement Services Harrisburg, Pennsylvania
Kendall Monroe Chief Advancement Officer Houston, Texas	Rosemary Chustak Patient Liaison Milwaukee, Wisconsin	Jeanette Stensgaard Senior Director of Events and Education Aurora, Colorado
LaRanda Burke Chief Finance and Operations Officer Houston, Texas	Christine Kelly-Weaver Executive Assistant Houston, Texas	Sarah Tuck Program Manager Langhorne, Pennsylvania
Susan Alanis Director of Gift Operations Houston, Texas	Melissa Lopez Gift Operations Associate Houston, Texas	Maggie Valdes Manager of Corporate Partnerships Houston, Texas
Christina Bargas Manager, Events and Education Denver, Colorado	Amy Marbaugh Director of Patient Programs Cleveland, Ohio	Jennifer Vitek Director of Conferences and Events Denver, Colorado
Ryan Cerezo Development Manager Lathrop, California	Emely Rodriguez Accountant Houston, Texas	Angela Washington Director of Operations Houston, Texas

BOARD OF DIRECTORS

Gretchen E. Vaughan, President and CEO	Ronald M. Bukowski, MD	David Perry, Esq.
Bradley C. Leibovich, MD (Chairperson)	Tessa Churchill, MD, MBA	Shelley Robson
Noah Buntman (Treasurer)	Craig DePriester	Brian Shuch, MD
Jamie Graves (Secretary)	Daniel J. George, MD	Joel Stern
Laurence Albiges, MD, PhD	Ryan Natzke	Laura Wood, RN, MSN, OCN
Mahul B. Amin, MD		Ruben Ybarra

MEDICAL STEERING COMMITTEE

Daniel J. George, MD (Chairperson)
Brian Rini, MD (Vice Chair)
Laurence Albiges, MD, PhD
Axel Bex, MD, PhD
Ronald M. Bukowski, MD (Emeritus)
Jose A. Karam, MD, FACS
Chung-Han Lee, MD, PhD
Bradley C. Leibovich, MD
Pavlos Msaouel, MD, PhD
Sumanta Pal, MD
W. Kimryn Rathmell, MD, PhD
Walter M. Stadler, MD, FACP (Emeritus)
Nizar M. Tannir, MD, FACP (Emeritus)
Tian Zhang, MD

CLINICAL ADVISORY BOARD

Laura S. Wood, RN, MSN, OCN (Chair)
Nancy Moldawer, RN, MSN (Co-Chair)
Nancy Ainslie, RN, BSN
Julia Batten, APRN, MSN, MPH
Patricia Fischer RN, MSN, OCN
Jan Jackson, RN
Kiran Virdee, RN, BSN, CCRN
Zita Lim, PA-C
Kathryn Nelson, RN
Virginia J. Seery, MSN, RN, ANP-BC

PATIENT & CAREGIVER ADVISORY COUNCIL

Ryan Natzke (Chair)
Kathleen Campbell
Steven Edwards
John Ferrell
Bruce Hill
Susan Hill
Vineeta Hiranandani
Ritchie Johnson
Benjamin Lundin
Deb Maskens
Marissa Willis
Salima Witt
Peggy Zuckerman

## CONTINUING MEDICAL EDUCATION INFORMATION

**TO CLAIM CREDIT:** Go to the web portal [eventscribe.net/2022/IKCSNA22/index.asp?launcher=1](https://eventscribe.net/2022/IKCSNA22/index.asp?launcher=1)

This activity is jointly provided by The France Foundation and The Kidney Cancer Association.



KidneyCancerAssociation®

### TARGET AUDIENCE

This educational activity is intended for medical oncologists and urologists who treat patients with kidney cancer. All other healthcare professionals involved in the management of kidney cancer are invited to participate.

### STATEMENT OF NEED

Education and interaction surrounding the space of renal cell carcinoma are paramount to improving patient care. This program is targeted to physicians, advocates, and researchers to help promote learning and collaboration for advancement in the renal cancer space.

### EDUCATIONAL ACTIVITY LEARNING OBJECTIVES

Upon completion of this course, the participants should be able to:

- Characterize the various therapies currently available for locally advanced and metastatic renal cell carcinoma
- Identify the novel approaches to non-clear RCC patient management
- Understand the role of the tumor microenvironment in kidney cancer
- Discuss how to design biomarker driven clinical trials in kidney cancer

### ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by The France Foundation and the Kidney Cancer Association. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

### CREDIT DESIGNATION

**Physicians:** The France Foundation designates this live activity for a maximum of 11.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT

1. Review the activity objectives and CME/CE information.
2. Participate in the CME/CE activity.
3. **TO CLAIM CREDIT:** Go to the web portal [eventscribe.net/2022/IKCSNA22/index.asp?launcher=1](https://eventscribe.net/2022/IKCSNA22/index.asp?launcher=1)  
Complete the evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
4. If you are requesting educational credits or a certificate of participation, your certificate will be available for download.

## DISCLOSURE POLICY

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and The Kidney Cancer Association (KCA) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and KCA resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and KCA see to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and KCA are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Please visit <https://bit.ly/3CO23zO>  
to view disclosures for all IKCS:  
North America Planners and Faculty.

## DISCLOSURE OF UNLABELED USE

TFF and KCA require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and KCA do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

## DISCLAIMER

TFF and KCA present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, KCA, and the commercial supporter(s) assume no liability for the information herein.

SOURCES OF FUNDING

Funding sources supporting this conference include the following:

- Participants’ registration fees
- Exhibition booths during the event

INFORMATION

If you have questions about this CME/CE activity, please contact The France Foundation at **860-434-1650** or **jchahal@francefoundation.com**

Virtual Only: QR code contains link to participate in session virtually.



SPONSORED SYMPOSIA LIST

Thursday, November 3 6:00pm – 7:00pm PRESENTED BY EISAI	<b>A First-line Treatment Option for Your Adult Patients With Advanced Renal Cell Carcinoma Faculty</b>	Sandy Liu, M.D. <i>Assistant Clinical Professor, Department of Medical Oncology and Therapeutics Research Medical Director of Genitourinary Medical Oncology, City of Hope Orange County</i>
Thursday, November 3 7:00pm – 8:00pm PRESENTED BY PEERVIEW	<b>RCC Clinical Consults: Making Difficult Treatment Decisions at the Intersection of the Data and the Real World</b>	PeerView Institute for Medical Education  Sumanta “Monty” K. Pal, MD, FASCO <i>City of Hope</i>
Friday, November 4 1:15pm – 2:15pm PRESENTED BY EXELIXIS	<b>A Combination Treatment for Patients with Advanced Renal Cell Carcinoma</b>	John Sarantopoulos, MD <i>UT Health San Antonio MD Anderson Cancer Center</i>
Friday, November 4 6:00pm–7:00pm PRESENTED BY MERCK	<b>A Treatment Option for Certain Patients With RCC in the Adjuvant Setting</b>	Amit Mehta, M.D.

SCAN TO ACCESS APP/HYBRID MEETING PLATFORM



For Mobile

1. Scan the QR code to access the platform on a mobile device
2. Log in with your email address and Access Key

For PC

1. Go to [eventscribe.net/2022/IKCSNA22/index.asp?launcher=1](https://eventscribe.net/2022/IKCSNA22/index.asp?launcher=1)
2. Log in with your email address and Access Key

To Submit a Question During a Session Q+A

1. Go to [eventscribe.net/2022/IKCSNA22/index.asp?launcher=1](https://eventscribe.net/2022/IKCSNA22/index.asp?launcher=1)
2. Log in with your email address and Access Key
3. Click Program, then open the session you wish to attend
4. To submit a question to speakers, click the Question button on the bottom right-hand corner of the window



Program Agenda • Thursday, November 3, 2022

1:30pm–7:00pm	Registration Open	
2:00pm–5:00pm	<b>KCA Think Tank sponsored by Pfizer - Non-CME (by Invitation Only)</b> BIG BEND BALLROOM	
5:00pm–6:00pm	<b>Welcome and First-time Attendee Happy Hour (In-person Only)</b> ZILKER TERRACE	
6:00pm–7:00pm	<b>Non-CME Symposium - Eisai A First-line Treatment Option for Your Adult Patients With Advanced Renal Cell Carcinoma</b> FULLY VIRTUAL	Sandy Liu, M.D. Assistant Clinical Professor, Department of Medical Oncology and Therapeutics Research Medical Director of Genitourinary Medical Oncology, City of Hope Orange County Irvine, CA
7:00pm – 8:00pm	<b>Non-CME Symposium - PeerView RCC Clinical Consults: Making Difficult Treatment Decisions at the Intersection of the Data and the Real World</b> HILL COUNTRY BALLROOM	PeerView Institute for Medical Education  Sumanta “Monty” K. Pal, MD, FASCO City of Hope



2023 IKCS: NA

Save  
the Date

November 10–11, 2023

Nashville, Tennessee



Program Agenda • Friday, November 4, 2022

6:30am–6:00pm	Registration Open	
7:45am–8:15am	Breakfast ZILKER 1 & 2 AND ZILKER FOYER	
6:30am–6:30pm	Poster and Exhibit Hall Open ZILKER 1 & 2 AND ZILKER FOYER	
6:45am–7:45am	Women in RCC sponsored by Exelixis - Non-CME BIG BEND BALLROOM A & B	<p>Session Chair/Moderator: Maria Carlo, MD <i>Memorial Sloan Kettering Cancer Center</i></p> <p>Elaine Chang, MD <i>Food and Drug Administration</i></p> <p>Vicki Goodman, MD <i>CEO, Exelixis</i></p> <p>W. Kimryn Rathmell, MD, PhD <i>Vanderbilt University Medical Center</i></p>
7:45am–8:00am	Break ZILKER 1 & 2 AND ZILKER FOYER	
8:00am–8:10am	Welcome, Day 1 ZILKER 3 & 4	<p>Eric A. Singer, MD, MA, MS, FACS, FASCO <i>The Ohio State University Comprehensive Cancer Center</i></p> <p>Tian Zhang, MD, MHS <i>University of Texas Southwestern Medical Center</i></p>

## Program Agenda • Friday, November 4, 2022

8:10am–10:00am	<b>Session 1: Treatment Debates in RCC ZILKER 3 &amp; 4</b>	Session Chair/Moderator: Vitaly Margulis, MD <i>University of Texas Southwestern</i>  Rana McKay, MD <i>UCSD</i>
8:10am–8:15am	<b>Debate 1: Surveillance vs Intervention Case Presentation</b>	Rana McKay, MD <i>UCSD</i>
8:15am–8:25am	<b>The Case for Surveillance</b>	Phillip M. Pierorazio, MD <i>Penn Medicine</i>
8:25am–8:35am	<b>The Case for Intervention</b>	Raquib Hannan, MD, PhD <i>University of Texas Southwestern</i>
8:35am–8:45am	<b>Debate Discussion 1: Surveillance vs Intervention</b>	
8:45am–8:50am	<b>Debate Discussion 2: Adjuvant or Not? Case Presentation</b>	Vitaly Margulis, MD <i>University of Texas Southwestern</i>
8:50am–9:00am	<b>The Case for Adjuvant Therapy</b>	Bradley McGregor, MD <i>Dana-Farber Cancer Institute</i>
9:00am–9:10am	<b>The Case for Not Adjuvant Therapy</b>	Naomi Balzer Haas, MD <i>Penn Medicine</i>
9:10am–9:20am	<b>Debate Discussion 2: Adjuvant or Not</b>	
9:20am–9:25am	<b>Debate Discussion 3: Doublet or Triplet as First-line Treatment in Kidney Cancer Case Presentation</b>	Vitaly Margulis, MD <i>University of Texas Southwestern</i>
9:25am–9:35am	<b>In Favor of Doublet Treatment</b>	Yousef Zakharia, MD <i>University of Iowa</i>
9:35am–9:45am	<b>In Favor of Triplet Treatment</b>	Rana McKay, MD <i>UCSD</i>

## Program Agenda • Friday, November 4, 2022

9:45am–9:55am	<b>Debate Discussion 3: Doublet vs Triplet</b>	
9:55am–10:00am	<b>Session 1 Wrap Up</b>	Vitaly Margulis, MD <i>University of Texas Southwestern</i>
	<b>Patient Perspective: Russ Nicholson</b>	
10:00am–11:00am	<b>Session 2: Side-effect Management and Quality of Life Perspectives ZILKER 3 &amp; 4</b>	Session Chair/Moderator: Elizabeth Wulff-Burchfield, MD <i>University of Kansas Medical Center</i>
10:00am–10:15am	<b>Quality of Life and Systemic Therapy for Renal Cell Carcinoma</b>	Elizabeth Wulff-Burchfield, MD <i>University of Kansas Medical Center</i>
10:15am–10:25am	<b>Patient Perspective on Side-effects and Care</b>	Laura Esfeller, MA <i>San Manuel Band of Mission Indians</i>
10:25am–10:30am	<b>Daily Aspects of Side-effect Management</b>	Kiran Virdee, RN CCRN-K <i>Memorial Sloan Kettering Cancer Center</i>
10:30am–11:00am	<b>Panel Discussion and Case Study: Navigating Renal Cell Carcinoma Side-effects Beyond Oncology and Urology</b>	Moderator: Elizabeth Wulff-Burchfield, MD <i>University of Kansas Medical Center</i>  Panelist: Kiran Virdee, RN CCRN-K <i>Memorial Sloan Kettering Cancer Center</i>  Panelist: Yan Liu, MD, PhD <i>Ascension Texas Cardiovascular</i>  Panelist: Afreen Shariff, MD, MBBS <i>Duke Health</i>  Panelist: Michael L. Dougan, MD, PhD <i>Massachusetts General Hospital and Harvard Medical School</i>
11:00am–11:30am	<b>Break</b> <b>ZILKER 1 &amp; 2 AND ZILKER FOYER</b>	

## Program Agenda • Friday, November 4, 2022

11:30am–11:50am	<b>Session 3: The Professional State of RCC</b> ZILKER 3 & 4	W. Kimryn Rathmell, MD, PhD <i>Vanderbilt University Medical Center</i>
11:50am–1:00pm	<b>Session 4: Professional Development Workshop</b> (In-person Only) ZILKER 3 & 4	Session Chair/Moderator: Eric A. Singer, MD, MA, MS, FACS, FASCO <i>The Ohio State University Comprehensive Cancer Center</i>  Tian Zhang, MD, MHS <i>University of Texas Southwestern Medical Center</i>
11:55am–12:30pm	<b>Breakout Group 1: Professional Development and What I Wish I Had Known 10 Years Ago</b>	Bradley C. Leibovich, MD <i>Mayo Clinic</i>  Tian Zhang, MD, MHS <i>University of Texas Southwestern Medical Center</i>  Daniel J. George, MD <i>Duke University Medical Center</i>
11:55am–12:30pm	<b>Breakout Group 2: Learning From Others’ Experience: How and When to Consider Career Moves</b>	Brian Rini, MD <i>Vanderbilt-Ingram Cancer Center</i>  Eric A. Singer, MD, MA, MS, FACS, FASCO <i>The Ohio State University Comprehensive Cancer Center</i>  W. Kimryn Rathmell, MD, PhD <i>Vanderbilt University Medical Center</i>  Jodi Maranchie, MD <i>University of Pittsburgh Medical Center</i>
11:55am–12:30pm	<b>Breakout Group 3: Career Opportunities in Industry and Options Outside Academia</b>	Subramanian Hariharan, MD, FACP <i>Pfizer Oncology</i>  Jose R. Perez, MD <i>Exelixis</i>  Bradley McGregor, MD <i>Dana-Farber Cancer Institute</i>

## Program Agenda • Friday, November 4, 2022

12:30pm–1:00pm	<b>Bringing it Back Together: Insights from Each Breakout Group and Q+A</b>	Eric A. Singer, MD, MA, MS, FACS, FASCO <i>The Ohio State University Comprehensive Cancer Center</i>  Tian Zhang, MD, MHS <i>University of Texas Southwestern Medical Center</i>
1:00pm–2:30pm	<b>Lunch and Posters</b> <b>ZILKER 1 &amp; 2 AND ZILKER FOYER</b>	
1:15pm–2:15pm	<b>Non-CME Symposium - A Combination Treatment for Patients with Advanced Renal Cell Carcinoma - Supported by Exelixis</b> <b>HILL COUNTRY BALLROOM</b>	John Sarantopoulos, MD <i>UT Health San Antonio MD Anderson Cancer Center</i>
2:30pm–3:15pm	<b>Session 5: Keynote</b> <b>ZILKER 3 &amp; 4</b>	Session Chair/Moderator: Tian Zhang, MD, MHS <i>University of Texas Southwestern Medical Center</i>
2:35pm–3:00pm	<b>Keynote Lecture: Kidney Cancer as a Model for a Curable Neoplasm</b>	David McDermott, MD <i>Beth Israel Deaconess Medical Center</i>
3:00pm–3:15pm	<b>Q&amp;A</b>	

## Program Agenda • Friday, November 4, 2022

3:15pm–4:30pm	<b>Session 6: Multidisciplinary Team Approaches to Rare Subtypes ZILKER 3–4</b>	Session Chair/Moderator: Jodi Maranchie, MD <i>University of Pittsburgh Medical Center</i>
3:15pm–3:25pm	<b>Collecting Duct and Sarcomatoid/ Rhabdoid Subtypes</b>	David A. Braun, MD, PhD <i>Yale School of Medicine</i>
3:25pm–3:35pm	<b>Biology and Management of Translocation Renal Cell Carcinoma</b>	Srinivas R. Viswanathan, MD, PhD <i>Dana-Farber Cancer Institute</i>
3:35pm–3:45pm	<b>Multidisciplinary Management of Renal Medullary Carcinoma</b>	Pavlos Msaouel, MD, PhD <i>University of Texas MD Anderson Cancer Center</i>
3:45pm–3:55pm	<b>Abstract 1: Spatial Molecular Imaging to Profile the Epithelial to Mesenchymal Transition and Immune Crosstalk in Sarcomatoid Renal Cell Carcinoma</b>	Allison May, MD <i>University of Michigan</i>
3:55pm–4:05pm	<b>Abstract 2: Biomarkers of Disease Burden and Treatment Response in Renal Medullary Carcinoma</b>	Kyle A. Blum, MD, MS <i>University of Texas Houston, MD Anderson Cancer Center</i>
4:05pm–4:30pm	<b>Panel Discussion and Q&amp;A: Best Practices for Multidisciplinary Care Teams</b>	Payal Kapur, MD <i>University of Texas Southwestern</i>  Ivan Pedrosa, MD, PhD <i>University of Texas Southwestern</i>  Steven Chang, MD, MS <i>Dana-Farber/Brigham and Women's Cancer Center</i>  Stephanie Berg, DO <i>Dana-Farber Cancer Institute</i>  Chad Tang, MD <i>University of Texas MD Anderson Cancer Center</i>

## Program Agenda • Friday, November 4, 2022

4:30pm–5:15pm	<b>Session 7: Academy of Kidney Cancer Investigators</b> ZILKER 3 & 4	Session Chair/Moderator: Brian Rini, MD <i>Vanderbilt-Ingram Cancer Center</i>
4:40pm–4:55pm	<b>Circulating Biomarkers in Renal Cell Carcinoma</b>	Wenxin Xu, MD <i>Dana-Farber Cancer Institute</i>
4:55pm–5:10pm	<b>Recurrent Genomic Alterations Driving Clear Cell Renal Cell Carcinoma Development</b>	Peter Ly, PhD <i>University of Texas Southwestern Medical Center</i>
5:10pm–5:15pm	<b>Panel Discussion and Q&amp;A</b>	
5:15 PM- 5:30 PM	<b>Remembering Nicholas J. Vogelzang, MD, FASCO, FACP</b> ZILKER 3 & 4	Brian Rini, MD <i>Vanderbilt-Ingram Cancer Center</i>
5:30pm–7:00pm	<b>Evening Reception sponsored by Exelixis</b> <i>Vintage Guitar Station and Social</i> <i>Media Wall available for guest</i> ZILKER 1 & 2 AND ZILKER FOYER	
5:45pm–6:30pm	<b>Poster Walks Sponsored by Pfizer (In-person Only)</b> ZILKER 1 & 2 AND ZILKER FOYER	Sumanta Kumar Pal, MD, FASCO <i>City of Hope</i>  Shawn Dason, MD <i>Ohio State University Medical Center</i>
5:45pm–6:30pm	<b>Poster Walks Sponsored by Pfizer (Online Only)</b>	Bradley McGregor, MD <i>Dana-Farber Cancer Institute</i>  Phillip M. Pierorazio, MD <i>Penn Medicine</i>
6:00pm–7:30pm	<b>Non-CME Symposium- Merck</b> A Treatment Option for Certain Patients With RCC in the Adjuvant Setting HILL COUNTRY BALLROOM	Amit Mehta, M.D. <i>Premier Hematology Oncology</i>

## Program Agenda • Saturday, November 5, 2022

6:30am–1:00pm	<b>Registration Open</b>	
6:30am–7:15am	<b>Group Run</b> ( <i>In-person only, advanced registration required</i> ) <b>HYATT HOTEL LOBBY</b>	Bradley McGregor, MD.
6:30am–7:30am	<b>Group Yoga</b> ( <i>In-person only, advanced registration required</i> ) <b>BIG BEND BALLROOM</b>	Phillip Pierorazio, MD.
7:45am–8:15am	<b>Breakfast</b> <b>ZILKER FOYER</b>	
6:30am–2:00pm	<b>Poster and Exhibit Hall Open</b> <b>ZILKER 1 &amp; 2 ZILKER FOYER</b>	
8:00am–8:15am	<b>Welcome, Day 2</b> <b>Updates from the KCA</b> ZILKER 3–4	Daniel J. George, MD <i>Duke University Medical Center</i>
8:15am–9:15am	<b>Session 8:</b> <b>Regulatory for New Trials</b> ZILKER 3–4	Session Chair/Moderator: Sumanta Kumar Pal, MD, FASCO <i>City of Hope</i>
8:15am–8:30am	<b>The New Era of Clinical Trials:</b> <b>Meeting Regulatory Requirements</b> <b>and Decreasing Barriers</b>	Elaine Chang, MD <i>United States Food and Drug Administration</i>
8:30am–8:45am	<b>Choosing Endpoints and</b> <b>Designs of Future Trials</b>	Chung-Han Joe Lee, BS, PhD, MD <i>Memorial Sloan Kettering Cancer Center</i>
8:45am–9:00am	<b>Experiences with Patient</b> <b>Acceptance of Clinical Trials</b>	Laura S. Wood, RN, MSN, OCN <i>Retired, Cleveland Clinic Cancer Center</i>
9:00am–9:05am	<b>Abstract 3:</b> <b>Assessment of Eligibility Criteria</b> <b>in Contemporary Renal Cell</b> <b>Carcinoma (RCC) Trials</b> <b>Evaluating Systemic Therapy</b>	Daniela V. Castro, MS <i>City of Hope Comprehensive Cancer Center</i>
9:05am–9:15am	<b>Panel Discussion and Q&amp;A</b>	



## Program Agenda • Saturday, November 5, 2022

9:15am–10:00am	<b>Session 9: Oral Abstract Session ZILKER 3 &amp; 4</b>	Yousef Zakharia, MD <i>University of Iowa and Holden Comprehensive Cancer Center</i>
9:15am–9:25am	<b>Abstract 5: CD200-mediated Immune Evasion in Clear Cell Renal Cell Carcinoma</b>	Gemma E. Davies, BSc, MSc <i>Cardiff University</i>  Alternate Presenter: Girish Patel, MD <i>Cardiff University</i>
9:25am–9:35am	<b>Abstract 6: Clinical Outcomes with Nivolumab/ Ipilimumab (nivo/ ipi) with or without CBM588 in Metastatic Renal Cell Carcinoma (mRCC): Long-term Follow-up of a Randomized Phase Ib Clinical Trial</b>	Nazli Dizman, MD <i>Yale New Haven Hospital</i>
9:35am–9:40am	<b>Abstract 7: Assessment of Clavien-Dindo Classification in patients with Metastatic Clear Cell Renal Cell Carcinoma (mccRCC) who Received Perioperative Cabozantinib and Nivolumab on Cyto-KIK Clinical Trial</b>	Karie Runcie, <i>New York Presbyterian Hospital; Columbia University</i>
9:40am–9:50am	<b>Abstract 8: Genetic Ancestry and Molecular Correlations in Patients with Kidney Cancers</b>	Ritesh Kotecha, MD <i>Memorial Sloan Kettering Cancer Center</i>
9:50am–10:00am	<b>Panel Discussion and Q&amp;A</b>	
	<b>Patient Perspective: Tom Cady</b>	
10:00am–10:15am	<b>Break</b> ZILKER 1 & 2 AND ZILKER FOYER	

## Program Agenda • Saturday, November 5, 2022

10:15am–11:45am	<b>Session 10: Genetics in Kidney Cancer Demonstrated Through Case-Based Presentations</b> ZILKER 3 & 4	Session Chair/Moderator: Maria Carlo, MD <i>Memorial Sloan Kettering Cancer Center</i>
10:15am–10:35am	<b>Considerations for the Genetics Consensus Statement and Who/What/When/Where/Why of Genetics in Kidney Cancer and Case Presentations Illustrating Options</b>	Brian Shuch <i>University of California, Los Angeles</i>
10:35am–10:55am	<b>Somatic Testing Considerations and Case Presentations</b>	Elizabeth Henske, MD <i>Brigham and Women's Hospital</i>
10:55am–11:15am	<b>BHD, TSC-associated RCC, HLRCC, FH deficient RCC, and VHL with Case Presentations</b>	Ramprasad Srinivasan, MD, PhD <i>National Cancer Institute at the National Institutes of Health</i>
11:15am–11:25am	<b>Abstract 9: Delineating Clinical and Radiologic Features of Rare Kidney Cancer Genetic Syndromes</b>	Pamela I. Causa Andrieu, MD <i>Memorial Sloan Kettering Cancer</i>
11:25am–11:45am	<b>Panel Discussion and Q&amp;A</b>	
11:45am–12:30pm	<b>Session 11: Risk Stratification: Considerations and the Evolving State of RCC</b>	Session Chair/Moderator: Katy Beckermann, MD, PhD <i>Vanderbilt University Medical Center</i>
11:45am–12:00pm	<b>Renal Cell Carcinoma Prognostic Factors</b>	Daniel YC Heng, MD <i>Tom Baker Cancer Centre, Calgary, AB, Canada</i>
12:00pm–12:15pm	<b>What's Wrong with the Guidelines and How Do We Move Forward?</b>	Ari Hakimi, MD <i>Memorial Sloan Kettering Cancer Center</i>
12:15pm–12:30pm	<b>Panel Discussion and Q&amp;A</b>	
12:30pm–1:30pm	<b>Break and Lunch Available</b> ZILKER 1 & 2 AND ZILKER FOYER	

## Program Agenda • Saturday, November 5, 2022

12:45pm–1:15pm	<b>Session 12: Kidney Cancer Association Awards Recognition</b> ZILKER 3 & 4	Session Chair/Moderator: Bradley C. Leibovich, MD <i>Mayo Clinic</i>
12:45pm–12:50pm	<b>Introduction:</b> <b>Eugene P. Schonfeld Award</b>	Bradley C. Leibovich, MD <i>Mayo Clinic</i>
12:50pm–12:55pm	<b>Eugene P. Schonfeld Award Presentation</b>	David McDermott, MD <i>Beth Israel Deaconess Medical Center</i>
12:55pm–1:00pm	<b>Introduction:</b> <b>Christopher G. Wood Rising Star Award</b>	Bradley C. Leibovich, MD <i>Mayo Clinic</i>
1:00pm–1:05pm	<b>Christopher G. Wood Rising Star Award Presentation</b>	Daniel Shapiro, MD <i>University of Wisconsin-Madison</i>
1:05pm–1:20pm	<b>Introduction:</b> <b>Nicholas J. Vogelzang Humanitarian Award</b>	Brian Rini, MD <i>Vanderbilt-Ingram Cancer Center</i>
1:20pm–1:25pm	<b>Nicholas J. Vogelzang Humanitarian Award Presentation</b>	Accepted by Dianne Vogelzang on behalf of the late Nicholas J. Vogelzang, MD, FASCO, FACP
1:25pm–2:25pm	<b>Session 13: WoodFire*</b> ZILKER 3 & 4	
1:25pm–1:40pm	<b>Case Discussion 1</b>	Daniel Shapiro, MD <i>University of Wisconsin-Madison</i>
1:40pm–1:55pm	<b>Case Discussion 2</b>	Vignesh T. Packiam, MD <i>University of Iowa</i>
1:55pm–2:10pm	<b>Case Discussion 3</b>	Walter Stadler, MD <i>University of Chicago</i>
2:10pm–2:25pm	<b>Case Discussion 4</b>	Rana McKay, McKay, MD <i>UCSD</i>
2:25pm–2:40pm	<b>Meeting Closing</b> ZILKER 3 & 4	Eric A. Singer, MD, MA, MS, FACS, FASCO <i>The Ohio State University Comprehensive Cancer Center</i>  Tian Zhang, MD, MHS <i>University of Texas Southwestern Medical Center</i>

\*WoodFire is a special chance to watch experts tackle difficult kidney cancer cases and defend their treatment plan. Each panelist presents a real clinical case including patient history and scans and asks their colleagues how they would treat and manage that patient. This spirited session captures what it's really like to be part of a care team!

## Poster Listings

POSTER BY TOPIC	BOARD #
Late-breaking Data Abstracts	E2
Regular Abstracts	A1-E1; E3-E7
Case Reports	E8
Trials in Progress Abstracts	F1-F7
Basic Science	A1-A2
Imaging	A3
Patient-reported Outcomes	A5
Post-treatment Surveillance	A6-A7
Quality of Care and Quality Improvement	A6-A7
Real-World Evidence	B4-C1
Therapeutics (Local- Primary and Metastases)	C4-C5
Therapeutics (Systemic- Radiation Therapy, Ablation, Surgery, Interventional Radiology, Urology, Medical Oncology, etc.)	C6-E1; F1-F7
Treatment Toxicities and Symptom Management	E3
Tumor Biology, Biomarkers, and Pathology	E4-E7
Other	A4, E8



**LENVIMA<sup>®</sup>**  
(lenvatinib) capsules | 10 mg and 4 mg

**Visit our exhibits  
to learn more**

 LENVIMA<sup>®</sup> is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.

© 2021 Eisai Inc. All rights reserved.  
Printed in USA/August 2021 LENV-US6455

POSTER BOARD #	TITLE	AUTHOR
A1	Abstract 9: DNA methylation-based tumor microenvironment deconvolution in clear cell renal cell carcinoma reveals significant survival association with specific cell types	Ze Zhang
A2	Abstract 10: Epigenetic Dysregulation Activates the Oncogenic Dicarboxylic Amino Acid Transporter SLC1A1 in ccRCC	Abhishek Chakraborty
A3	Abstract 11: Differentiation Clear Cell Renal Cell Carcinoma from Other Common Malignant and Benign Renal Masses on Multiphasic MRI: A Likert Based Multireader Analysis	Chuthaporn Surawech Alternate Presenter: Steve Raman
A4	Abstract 12: Outcomes of active surveillance for young and healthy patients with small renal masses	Muammer Altok
A5	Abstract 13: The Role of Exercise on the Physical and Mental Health of Kidney Cancer Patients and Survivors	Daniel Roberson
A6	Abstract 14: Risk factors for end stage renal disease after treatment of renal cell carcinoma	Sven Lundstam
A7	Abstract 15: Survival Outcomes Following Adoption of Risk-Adjusted AUA Surveillance Guidelines After Partial Nephrectomy	Wesley Yip
A8	Abstract 16: Artificial intelligence modelling to predict the risk of cardiotoxicity among renal cell carcinoma patients treated with vascular endothelial growth factor receptors tyrosine kinase inhibitors.	Hesham Yasin
B1	Abstract 17: Kidney cancer clinical trials: a decision aid for patients and clinicians Presenter:	Rachel Giles Alternative Presenter: Eric Jonasch
B2	Abstract 18: Non-Index vs Index Readmissions Following Radical Nephrectomy: Causes, Costs, and Outcomes	Shiva Balasubramanian
B3	Abstract 19: Non-Index vs Index Readmissions Following Partial Nephrectomy: Causes, Costs, and Outcomes	Shiva Balasubramanian
B4	Abstract 20: Real-world Clinical Outcomes of Patients (pts) with Metastatic Renal Cell Carcinoma (mRCC) Receiving Pembrolizumab + Axitinib (P+A) vs Ipilimumab + Nivolumab (I+N)	Neil J. Shah

POSTER BOARD #	TITLE	AUTHOR
B5	Abstract 21: Short-Term Outcomes of Active Surveillance for Small Renal Masses in Patients With End-Stage Renal Disease and Immunosuppression	Zoe Gan
B6	Abstract 22: Healthcare resource utilization (HCRU) and costs in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line (LOT1) pembrolizumab + axitinib (P+A) or ipilimumab + nivolumab (I+N)	Neil J. Shah
B7	Abstract 23: Real-world Assessment of Changing Treatment Patterns and sequence for patients with Metastatic Renal Cell Carcinoma (mRCC) in the first-line (1L) setting	Neil J. Shah
B8	Abstract 24: Depth of response associated with first-line immunotherapy-based combinations in metastatic clear cell renal cell carcinoma.	Kelly Fitzgerald
C1	Abstract 25: Clinical manifestations of Birt-Hogg-Dube Syndrome in a large clinical cohort	Raju Chelluri
C4	Abstract 28: Treatment decisions among patients newly diagnosed with clinical T1 renal masses	Kathryn Gessner
C5	Abstract 29: Cytoreductive nephrectomy (CN) for patients with metastatic sarcomatoid and/or rhabdoid (S/R) renal cell carcinoma (RCC) treated with immune checkpoint therapy (ICT)	Andrew Hahn
C6	Abstract 30: Treatment-free survival (TFS) in patients with advanced renal cell carcinoma (aRCC) treated with nivolumab and ipilimumab (NIVO/IPI) versus sunitinib (SUN): 60-month update of Checkmate 214	Charlene Mantia
C7	Abstract 31: Updated efficacy of lenvatinib + pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma (aRCC) in the CLEAR study	Camilo G. Porta Alternative Presenter: Bradley McGregor
C8	Abstract 32: Efficacy and safety of nivolumab plus ipilimumab versus sunitinib for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up	Nazir Tannir
D1	Abstract 33: Long-term PFS from TIVO-3: Tivozanib (TIVO) vs sorafenib (SOR) in relapsed/refractory (R/R) advanced RCC	Michael Atkins
D2	Abstract 34: Characterization of Patients Undergoing Consolidative Nephrectomy after Immunotherapy	Stephen Reese



POSTER BOARD #	TITLE	AUTHOR
D3	Abstract 35: Activity of tivozanib in non-clear cell renal cell carcinoma (nccRCC): Subgroup analysis from a phase 2 randomized discontinuation trial	Pedro Barata
D4	Abstract 36: Impact of subsequent therapies in patients with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab or sunitinib in the CLEAR study	Martin H. Voss
D5	Abstract 37: A randomized phase 2 study with a cell-based immune primer plus sunitinib versus sunitinib alone in metastatic Renal Cell Carcinoma.	Börje Ljungberg
D6	Abstract 38: Association between depth of response (DepOR) and clinical outcomes: exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER	Andrea Apolo Alternative Presenter: Bernard Escudier
D7	Abstract 39: Maturation of overall survival (OS) in TIVO-3 with long-term follow-up	Brian Rini

**Genentech**  
A Member of the Roche Group

**THEIR FIGHT.  
OUR MISSION.**

Pioneering together for  
a cancer-free tomorrow.

[gene.com](http://gene.com)



POSTER BOARD #	TITLE	AUTHOR
D8	Abstract 40: Phase 1 trial of combination therapy with avelumab and cabozantinib in patients with newly diagnosed metastatic clear cell renal cell carcinoma	Haoran Li
E1	Abstract 41: Efficacy of nivolumab plus ipilimumab in T1aNOMO renal cell carcinoma patients ineligible for surgery and ablation	Ilya Tsimafeyeu
E3	Abstract 43: Risk of Thromboembolism in Patients Receiving Immunotherapy-Based Combinations for Metastatic Renal Cell Carcinoma	James Schuster
E4	Abstract 44: NF2-Mutant Renal Cell Carcinoma: A Comprehensive Characterization of a Lethal Unclassified Renal Cell Carcinoma	Stephen Reese
E5	Abstract 45: Metagenomic analysis of the gut microbiome in metastatic renal cell carcinoma patients with sarcopenia	Neal Chawla
E6	Abstract 46: Prospective evaluation of mutation concordance between standard-of-care renal mass biopsy and nephrectomy specimens in small renal masses	Kathryn Gessner
E7	Abstract 47: Epigenetic, transcriptional, and compositional shifts in clear cell renal cell carcinomas	Lucas Salas
E8	Abstract 48: A Case of Metastatic Renal Cell Carcinoma to The Maxillary Sinus Initially Presenting as Recurrent Epistaxis	Justin Mehr
F1	Abstract 49: A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL / Alliance A031801)	Rana McKay
F2	Abstract 50: TiNivo-2: A Phase 3 Study to Compare Tivozanib+Nivolumab to Tivozanib Monotherapy in Patients with Renal Cell Carcinoma (RCC) Who Have Progressed Following $\leq 2$ Lines of Therapy including an Immune Checkpoint Inhibitor (ICI)	Toni Choueir
F3	Abstract 51: A phase II study of lenvatinib plus everolimus versus cabozantinib in patients with metastatic renal cell carcinoma (mRCC) that progressed on a PD-1/PD-L1 checkpoint inhibitor (LenCabo)	Andrew Hahn



POSTER BOARD #	TITLE	AUTHOR
F4	Abstract 52: LITESPARK-011: a randomized, phase 3 study of belzutifan plus lenvatinib versus cabozantinib after anti-PD-1/PD-L1 therapy in patients with advanced renal cell carcinoma	Daniel YC Heng
F5	Abstract 53: Phase 2 trial for sequential treatment after cabozantinib progression in metastatic renal cell carcinoma (Seq-Cabo)	Qian Qin
F6	Abstract 54: APART – A Phase 2 trial of Axitinib, Palbociclib and Avelumab as advanced Clear Cell Renal Cell Carcinoma (ccRCC) Therapy	Stephanie Berg
F7	Abstract 55: A pilot study of the immunomodulatory agent acarbose in combination with standard therapy in metastatic renal cell carcinoma (RCC)	Arnab Basu



Transforming patients' lives through science™

Every day, we focus on innovations that drive meaningful breakthroughs so we can bring life-saving medicines to people around the world.

 Bristol Myers Squibb™

Visit [bms.com](https://bms.com) to see how we're bringing a human touch to everything we do.

© 2022 Bristol Myers Squibb Company. All rights reserved.

Strong alone  
Unstoppable  
together.®

**KIDNEYCANCER.ORG**

# Sponsors and Exhibitors

2022 IKCS: North America is made possible with  
the generous support of our Sponsors:

## DIAMOND



## GOLD



## SILVER



## BRONZE



## EXHIBITORS


Visit the Exhibit Hall in Zilker 1-2

Aveo  
BackTable Urology  
BMS  
Eisai

Exelixis  
Genentech  
Kidney Cancer Association

Kidney Cancer Journal  
Merck  
Pfizer  
SAIL

# Hyatt Regency Austin: Zilker Ballroom 1 & 2





# KidneyCancerAssociation®

The Kidney Cancer Association is a global community dedicated to serving and empowering patients and caregivers, and leading change through advocacy, research, and education in order to be the universal leader in finding a cure for kidney cancer.

**KIDNEYCANCER.ORG**

**office@kidneycancer.org | 800-850-9132**

**MAILING ADDRESS**

9450 SW Gemini Drive #38269  
Beaverton, OR 97008-7105

**DONATION ADDRESS**

PO Box 676226  
Dallas, TX 75267-6226

**HQ IN HOUSTON TEXAS**

**#UnstoppableTogether**

**@KidneyCancerAssociation | @KidneyCancer**

